Differences in the involvement of prostanoids from Kupffer cells in the mediation of anaphylatoxin C5a-, zymosan-, and lipopolysaccharide-dependent hepatic glucose output and flow reduction.
Various inflammatory stimuli such as anaphylatoxin C5a, zymosan, and lipopolysaccharides (LPSs) have been reported both to enhance glucose output in the perfused rat liver and to induce prostanoid (ie, prostaglandin and thromboxane) release from Kupffer cells, the resident liver macrophages. Because prostanoids can enhance glucose output from hepatocytes, it was the aim of this study to compare the possible roles of prostanoids released after C5a, zymosan, and LPS in the mediation of hepatic glucose output. In perfused livers both C5a and zymosan immediately enhanced glucose output, reduced flow, and induced prostanoid overflow into the hepatic vein, but with different quantities and kinetics. Only the C5a-induced but not the zymosan-induced effects were abrogated by inhibitors of prostanoid signaling as the prostanoid synthesis inhibitor indomethacin and the thromboxane receptor antagonist daltroban. In contrast to C5a and zymosan, LPS had no effect on glucose output, flow rate, or prostanoid overflow. In isolated Kupffer cells, C5a and zymosan induced maximal release of prostaglandins D(2) and E(2) and of thromboxane A(2) within a period of 0 to 2 minutes and 5 to 15 minutes, respectively. In pulse-chase experiments, maximal prostanoid release was already observed after 2 minutes of continuous stimulation with C5a, but only after 10 to 15 minutes of continuous stimulation with zymosan. LPS-dependent prostanoid release was not seen before 1 hour. Thus, even though C5a, zymosan, and LPS induced prostanoid release from Kupffer cells, only C5a quickly regulated hepatic glucose metabolism in a prostanoid-dependent manner (due to the kinetics and quantities of prostanoids released).
Pestel
Sabine
S
Institute of Biochemistry and Molecular Cell Biology, Georg-August-University Goettingen, Goettingen, Germany.
Schlaf
Gerald
G
Götze
Otto
O
Jungermann
Kurt
K
Schieferdecker
Henrike L
HL
D000818:Animals; D002478:Cells, Cultured; D015936:Complement C5a / Q000494:pharmacology*; D004926:Escherichia coli / Q000276:immunology; D005947:Glucose / Q000378:metabolism; D006439:Hemodynamics / Q000187:drug effects; D022781:Hepatocytes / Q000187:drug effects / Q000473:pathology; D007213:Indomethacin / Q000494:pharmacology; D007728:Kupffer Cells / Q000187:drug effects* / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D008297:Male; D010477:Perfusion; D010648:Phenylacetates / Q000494:pharmacology; D011453:Prostaglandins / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D013449:Sulfonamides / Q000494:pharmacology; D013931:Thromboxanes / Q000378:metabolism; D015054:Zymosan / Q000494:pharmacology*
D008070:Lipopolysaccharides; D010648:Phenylacetates; D011453:Prostaglandins; D013449:Sulfonamides; D013931:Thromboxanes; D015936:Complement C5a; D015054:Zymosan; D005947:Glucose; C051762:daltroban; D007213:Indomethacin